Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)

被引：0
|
作者：
Mastrantoni, L. [1 ]
Garufi, G. [1 ]
Di Monte, E. [2 ]
Arcuri, G. [1 ]
Frescura, V. [1 ]
Maliziola, N. [3 ]
Rotondi, A. [3 ]
Giordano, G. [4 ]
Carbognin, L. [5 ]
Fabi, A. [6 ]
Paris, I. [7 ]
Franceschini, G. [8 ]
Orlandi, A. [9 ]
Palazzo, A. [10 ]
Puglisi, F. [11 ]
Dieci, M. V. [12 ]
Milella, M. [13 ]
Scambia, G. [14 ]
Tortora, G. [15 ]
Bria, E. [16 ]
机构：
[1] Univ Cattol Sacro Cuore, Dept Med Oncol, Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Clin Oncol, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
[4] Univ Cattolica Sacro Cuore, Geriatr, Rome, Italy
[5] Fdn Policlin Univ Agostino Gemelli IRCCS, Div Gynecol Oncol, Dept Woman & Child Hlth, Rome, Italy
[6] Fdn Policlin Univ A Gemelli, Precis Med Unit Senol, Rome, Italy
[7] Univ Cattolica Sacro Cuore, Dept Gynecol Oncol, Rome, Italy
[8] Fdn Policlin Univ Agostino Gemelli IRCCS, Senol, Rome, Italy
[9] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Oncol Med, Rome, Italy
[10] Fdn Policlin Univ Agostino Gemelli IRCCS, Sci Gastroenterol Endocrino Metab & Nefrourol, Rome, Italy
[11] ASU Friuli Centrale Osped S Maria Misericordia, Dept Med Oncol, Udine, Pordenone, Italy
[12] Univ Padua, DiSCOG, Padua, Italy
[13] Univ Verona, Med Oncol 1, Fac Med, Verona, Italy
[14] Fdn Policlin Univ Agostino Gemelli IRCCS, Women Children & Publ Hlth Sci, Rome, Italy
[15] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[16] Fdn Policlin Univ Agostino Gemelli IRCCS, Translat Med & Surg Dept, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.473
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
276P
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 12 条
  • [1] Artificial intelligence (AI)-based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study
    Mastrantoni, Luca
    Garufi, Giovanna
    Maliziola, Noemi
    Di Monte, Elena
    Arcuri, Giorgia
    Frescura, Valentina
    Rotondi, Angelachiara
    Giordano, Giulia
    Carbognin, Luisa
    Fabi, Alessandra
    Paris, Ida
    Marazzi, Fabio
    Antonio, Franco
    Franceschini, Gianluca
    Orlandi, Armando
    Palazzo, Antonella
    Scambia, Giovanni
    Tortora, Giampaolo
    Bria, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Development of Artificial Intelligence-based Machine Learning Models for Predicting Survival In Hormone-Receptor-Positive/HER2-Negative Early Breast Cancer undergoing Neoadjuvant Chemotherapy
    Mastrantoni, Luca
    Garufi, Giovanna
    Maliziola, Noemi
    Di Monte, Elena
    Arcuri, Giorgia
    Frescura, Valentina
    Rotondi, Angelachiara
    Giordano, Giulia
    Carbognin, Luisa
    Fabi, Alessandra
    Paris, Ida
    Franceschini, Gianluca
    Orlandi, Armando
    Palazzo, Antonella
    Scambia, Giovanni
    Tortora, Giampaolo
    Bria, Emilio
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Development and External Validation of a Machine Learning Model to Predict Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
    Jung, Ji-Jung
    Kim, Eun-Kyu
    Kang, Eunyoung
    Kim, Jee Hyun
    Kim, Se Hyun
    Suh, Koung Jin
    Kim, Sun Mi
    Jang, Mijung
    Yun, Bo La
    Park, So Yeon
    Lim, Changjin
    Han, Wonshik
    Shin, Hee-Chul
    JOURNAL OF BREAST CANCER, 2023, 26 (04) : 353 - 362
  • [4] Validation of Magee equation in predicting response to neoadjuvant chemotherapy in breast cancer patients with hormone receptor positive and HER2 negative
    Saigosoom, N.
    O-charoenrat, P.
    Udompunturak, S.
    Sanguanraksa, D.
    BREAST, 2019, 44 : S73 - S73
  • [5] The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Saigosoom, Napat
    Sa-nguanraksa, Doonyapat
    O-charoenrat, Eng
    Thumrongtaradol, Thanawat
    O-charoenrat, Pornchai
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 2491 - 2499
  • [6] Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)
    Eiermann, W.
    Baselga, J.
    Semiglazov, V.
    Byakhov, M.
    Ciruelos, E.
    Ojeda, B.
    Feyereislova, A.
    Zambetti, M.
    Valagussa, P.
    Gianni, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 115 - 115
  • [7] ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR).
    Earl, Helena Margaret
    Hiller, Louise
    Blenkinsop, Clare
    Grybowicz, Louise
    Vallier, Anne-Laure
    Abraham, Jean
    Thomas, Jeremy
    Provenzano, Elena
    Hughes-Davies, Luke
    McAdam, Karen
    Chan, Steve
    Ahmad, Rizvana
    Hickish, Tamas
    Houston, Stephen
    Rea, Daniel
    Bartlett, John M. S.
    Caldas, Carlos
    Cameron, David A.
    Dunn, Janet
    Hayward, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR
    Omranipour, Ramesh
    Jalili, Roghiyeh
    Yazdankhahkenary, Adel
    Assarian, Abdolali
    Mirzania, Mehrzad
    Eslami, Bita
    EUROPEAN JOURNAL OF BREAST HEALTH, 2020, 16 (03) : 213 - 218
  • [9] Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
    In Hee Lee
    Soo Jung Lee
    Jeeyeon Lee
    Jin Hyang Jung
    Ho Yong Park
    Shin Young Jeong
    Sang-woo Lee
    Yee Soo Chae
    BMC Cancer, 20
  • [10] Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
    Lee, In Hee
    Lee, Soo Jung
    Lee, Jeeyeon
    Jung, Jin Hyang
    Park, Ho Yong
    Jeong, Shin Young
    Lee, Sang-woo
    Chae, Yee Soo
    BMC CANCER, 2020, 20 (01)
12